We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Next-Gen Sequencing Method Predicts Prostate Cancer Risks

By LabMedica International staff writers
Posted on 08 Jan 2019
Print article
Image: A comparison of OncoScan array CGH assay–derived metastasis potential scores (MPSs) for indolent primary tumor (iPT) and metastasis-prone primary tumor (mPT) samples (Photo courtesy of Albert Einstein College of Medicine).
Image: A comparison of OncoScan array CGH assay–derived metastasis potential scores (MPSs) for indolent primary tumor (iPT) and metastasis-prone primary tumor (mPT) samples (Photo courtesy of Albert Einstein College of Medicine).
Prostate cancer is the most commonly diagnosed male cancer and the second leading cause of cancer deaths among men in the USA, with approximately 220,000 new diagnoses and approximately 27,000 deaths each year.

Men with clinical low-risk disease can receive active surveillance to safely preserve quality of life, provided that the risk of an undetected aggressive cancer can be managed. Clinical tests for the prognosis of prostate cancer from radical prostatectomy specimens and biopsy specimens are being increasingly used to inform treatment and active surveillance protocols.

A team of scientists led by those at the Albert Einstein College of Medicine (Bronx, NY, USA) collected from prostate cancer radical prostatectomy cohort of 72 men was collected at Duke University. A total of 88 prostate cancer surgical research (PCSR) samples (from 69 unique men) and 21 healthy samples were microdissected and underwent DNA extraction. A second prostate cancer cohort comprised 12 PCSR samples with matched punched biopsy samples (Duke Cohort 2). All PCSR samples (Duke Cohorts 1 and 2) were assayed on the OncoScan formalin-fixed, paraffin-embedded (FFPE) version 3 array and on the Next Generation Copy Number Alteration NG-CNA panel.

The team developed a genomic DNA signature, the metastatic potential score (MPS), and verified it as highly predictive of prostate cancer, triple-negative breast cancer, and lung adenocarcinoma metastases using surgical samples. Metastases and metastasis-prone primary tumors demonstrated enrichment of specific CNAs in one direction, either gain or loss. This directionality provided a basis for calculating scores for the specific genes within the CNA regions that included a penalty when the CNA went against the expected directionality.

The team reported that the NG-CAN assay can analyze 902 genomic sites across 194 genomic regions, which it can do both faster than existing tests and at a lower cost. With the NG-CNA, the cost of DNA extraction, library preparation, and sequencing reagents can be USD 20 to USD 40 per sample, compared to nearly USD 1,000 for whole genome sequencing. The team noted that the results that they obtain through the new test are easier to read, allowing scientists to process thousands of tissue samples in one go. NG-CNA also has a quicker turnaround time for the results, at approximately 36 hours. Finally, NG-CNA calls for the collection of smaller samples than other tests currently in use. The sample size can be as low as 12.5 ng of material, which would allow specialists to use the test to analyze cell lines, biopsy samples, and surgical samples.

Harry Ostrer, MD, a medical geneticist and lead author of the study said, “We have demonstrated that CNAs can be detected rapidly and accurately with the new Next-Generation Copy Number Alteration (NG-CNA) assay. We believe the addition of the NG-CNA assay onto a standard cancer gene testing platform will augment personalized medicine by identifying aggressive tumors and genetic mutations that are predictors of response to targeted therapies.” The study was published on December 12, 2018, in The Journal of Molecular Diagnostics.

Related Links:
Albert Einstein College of Medicine

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.